• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱癌患者非肌肉浸润性膀胱癌随访中膀胱 EpiCheck 试验的诊断预测价值。

Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.

机构信息

Department of Urology, Central Hospital of Bolzano, Bolzano, Italy.

Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy.

出版信息

Cancer Cytopathol. 2019 Jul;127(7):465-469. doi: 10.1002/cncy.22152. Epub 2019 Jun 2.

DOI:10.1002/cncy.22152
PMID:31154670
Abstract

BACKGROUND

The objective of this study was to evaluate the diagnostic accuracy of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer (NMIBC) and to compare it with the accuracy of urinary cytology, cystoscopy, and/or histology.

METHODS

In total, 243 patients were enrolled in the current study. Patients were evaluated by voided urine cytology, by the Bladder EpiCheck test, and by white-light cystoscopy.

RESULTS

Overall sensitivity was 33.3% for cytology, 62.3% for Bladder EpiCheck, and 66.7% for the 2 tests combined. The sensitivity of cytology increased from 7.7% in low-grade (LG) tumors to 66.6% in high-grade (HG) tumors; whereas, for the Bladder EpiCheck test, the sensitivity was 46.1% in LG tumors and 83.3% in HG tumors. Combined cytology and Bladder EpiCheck testing yielded an overall sensitivity of 56.4% for LG tumors and 90% for HG tumors. Overall specificity was 98.6% for cytology, 86.3% for Bladder EpiCheck, and 85.6% for the 2 tests combined. The positive predictive value was 92% for cytology and 68.2% for Bladder EpiCheck. For the 2 tests combined, it was 68.6%. The negative predictive value was similar for the 2 tests: 75.8% for cytology, 82.9% for Bladder EpiCheck, and 84.5% for the 2 tests combined.

CONCLUSIONS

The sensitivity of the Bladder EpiCheck test was significantly higher than that of cytology. The test performed very well in terms of specificity but could not reach the high value of cytology. The positive predictive value was higher for Bladder EpiCheck, whereas the negative predictive value was approximately the same for both tests.

摘要

背景

本研究旨在评估 Bladder EpiCheck 检测在非肌层浸润性膀胱癌(NMIBC)患者随访中的诊断准确性,并与尿细胞学、膀胱镜检查和/或组织学的准确性进行比较。

方法

本研究共纳入 243 例患者。患者通过尿液细胞学检查、膀胱 EpiCheck 检查和白光膀胱镜检查进行评估。

结果

细胞学检查的总敏感性为 33.3%,膀胱 EpiCheck 检查的敏感性为 62.3%,两者联合检查的敏感性为 66.7%。细胞学检查的敏感性从低级别(LG)肿瘤的 7.7%增加到高级别(HG)肿瘤的 66.6%;而对于膀胱 EpiCheck 检查,LG 肿瘤的敏感性为 46.1%,HG 肿瘤的敏感性为 83.3%。联合细胞学和膀胱 EpiCheck 检查的总敏感性分别为 LG 肿瘤的 56.4%和 HG 肿瘤的 90%。细胞学检查的总特异性为 98.6%,膀胱 EpiCheck 检查的特异性为 86.3%,两者联合检查的特异性为 85.6%。细胞学检查的阳性预测值为 92%,膀胱 EpiCheck 检查的阳性预测值为 68.2%。对于两种检查联合,阳性预测值为 68.6%。两种检查的阴性预测值相似:细胞学检查为 75.8%,膀胱 EpiCheck 检查为 82.9%,两种检查联合的阴性预测值为 84.5%。

结论

膀胱 EpiCheck 检查的敏感性明显高于细胞学检查。该检查在特异性方面表现出色,但无法达到细胞学检查的高值。膀胱 EpiCheck 检查的阳性预测值较高,而两种检查的阴性预测值大致相同。

相似文献

1
Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.膀胱癌患者非肌肉浸润性膀胱癌随访中膀胱 EpiCheck 试验的诊断预测价值。
Cancer Cytopathol. 2019 Jul;127(7):465-469. doi: 10.1002/cncy.22152. Epub 2019 Jun 2.
2
Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.比较两种新的基于实时聚合酶链反应的尿标志物在非肌肉浸润性膀胱癌患者随访中的应用。
Cancer Cytopathol. 2020 May;128(5):341-347. doi: 10.1002/cncy.22246. Epub 2020 Jan 24.
3
Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.《膀胱癌 EpiCheck™ 甲基化检测用于非肌层浸润性膀胱癌监测患者的性能:一项多中心、前瞻性、盲法临床试验结果》。
Eur Urol Oncol. 2018 Sep;1(4):307-313. doi: 10.1016/j.euo.2018.06.011. Epub 2018 Jul 17.
4
Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.Xpert 膀胱癌监测仪在非肌肉浸润性膀胱癌患者随访中的诊断预测价值。
J Clin Pathol. 2019 Feb;72(2):140-144. doi: 10.1136/jclinpath-2018-205393. Epub 2018 Oct 24.
5
The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.膀胱上皮检查试验及细胞学检查在非肌层浸润性高级别膀胱癌患者随访中的应用
Urol Oncol. 2022 Mar;40(3):108.e19-108.e25. doi: 10.1016/j.urolonc.2021.11.013. Epub 2021 Dec 10.
6
Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.新型尿液生物标志物 ADXBLADDER 和膀胱 EpiCheck 用于膀胱癌诊断:综述。
Urol Oncol. 2021 Mar;39(3):161-170. doi: 10.1016/j.urolonc.2020.11.014. Epub 2020 Dec 26.
7
Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.基于 RT-PCR 的尿标志物 Bladder Epicheck®在上尿路肿瘤中的诊断价值的前瞻性评估。
Minerva Urol Nephrol. 2024 Apr;76(2):195-202. doi: 10.23736/S2724-6051.23.05488-5. Epub 2024 Mar 18.
8
The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.膀胱上皮细胞检测试验在非肌肉浸润性膀胱癌患者随访中的作用。
Clin Genitourin Cancer. 2022 Aug;20(4):e271-e275. doi: 10.1016/j.clgc.2022.03.009. Epub 2022 Mar 16.
9
Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.在低风险非肌层浸润性膀胱癌患者随访中用尿液标志物取代膀胱镜检查?——一项国际膀胱癌网络项目。
Urol Oncol. 2016 Oct;34(10):452-9. doi: 10.1016/j.urolonc.2016.06.001. Epub 2016 Jul 2.
10
Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.使用计算机断层扫描(CT)尿路造影、软性膀胱镜检查和尿液细胞学检查评估膀胱癌的诊断策略:来自医院血尿诊所的 778 例患者的结果。
BJU Int. 2012 Jul;110(1):84-94. doi: 10.1111/j.1464-410X.2011.10664.x. Epub 2011 Nov 28.

引用本文的文献

1
Unleashing the potential of urine DNA methylation detection: Advancements in biomarkers, clinical applications, and emerging technologies.释放尿液DNA甲基化检测的潜力:生物标志物、临床应用及新兴技术的进展
Curr Urol. 2025 Sep;19(5):295-302. doi: 10.1097/CU9.0000000000000291. Epub 2025 Jul 19.
2
DNA Methylation in Urine and Feces Indicative of Eight Major Human Cancer Types Globally.尿液和粪便中的DNA甲基化可指示全球八大主要人类癌症类型。
Life (Basel). 2025 Mar 17;15(3):482. doi: 10.3390/life15030482.
3
Bladder cancer biomarkers.膀胱癌生物标志物
Explor Target Antitumor Ther. 2025 Mar 25;6:1002301. doi: 10.37349/etat.2025.1002301. eCollection 2025.
4
North American study and meta-analysis evaluating performance of Bladder EpiCheck, a FDA cleared test, in non-muscle invasive bladder cancer recurrence.一项北美研究及荟萃分析,评估经美国食品药品监督管理局批准的检测方法“膀胱EpiCheck”在非肌层浸润性膀胱癌复发方面的表现。
Bladder Cancer. 2025 Jan 15;10(4):278-289. doi: 10.1177/23523735241304348. eCollection 2024 Dec.
5
Predictive value of Bladder EpiCheck in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer.膀胱EpiCheck在检测非肌层浸润性膀胱癌二次经尿道膀胱肿瘤电切术前残留肿瘤中的预测价值。
World J Urol. 2025 Jan 27;43(1):89. doi: 10.1007/s00345-025-05453-3.
6
Bladder cancer detection in urine by novel methylation markers.新型甲基化标志物在尿液中检测膀胱癌。
Sci Rep. 2024 Nov 20;14(1):28705. doi: 10.1038/s41598-024-77781-0.
7
Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study.基于尿液甲基化标志物 GHSR/MAL 检测膀胱癌:一项验证性研究。
World J Urol. 2024 Oct 16;42(1):578. doi: 10.1007/s00345-024-05287-5.
8
The Simultaneous Use of Bladder Epicheck and Urinary Cytology Can Improve the Sensitivity and Specificity of Diagnostic Follow-Up of Urothelial Lesions: Up-to-Date Data from a Multi-Institutional Cohort.膀胱上皮检查与尿细胞学联合应用可提高尿路上皮病变诊断随访的敏感性和特异性:来自多机构队列的最新数据
Diseases. 2024 Sep 18;12(9):219. doi: 10.3390/diseases12090219.
9
Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.新兴生物活性技术与材料在膀胱癌诊断中对尿游离DNA的分析
Front Bioeng Biotechnol. 2024 Sep 4;12:1458362. doi: 10.3389/fbioe.2024.1458362. eCollection 2024.
10
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays.用于膀胱癌检测和监测的非侵入性检测:对市售检测方法的系统评价
Bladder Cancer. 2024 Mar 12;10(1):71-81. doi: 10.3233/BLC-230096. eCollection 2024.